Predicting antiarrhythmic performance

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 2, 1999, Pages 302-306

  Pratt, Craig M ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiarrhythmic drugs; Arrhythmic death

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLECAINIDE; MEXILETINE; PLACEBO; PROPAFENONE; QUINIDINE; SOTALOL; TOCAINIDE;

CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG EFFICACY; HEART ATRIUM ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MORTALITY; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; REVIEW; TORSADE DES POINTES;

EID: 0033045367     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00675.x     Document Type: Review

References (35)

1. Reiffel JA, Correia J: "In the absence of structural heart disease . . ." What is it, and why does it matter in antiarrhythmic drug therapy? (Editorial) Am Heart J 1994;128:626-629.
2. Pogwizd SM, Corr P: Reentrant and non-reentrant mechanisms contribute to arrhythmogenesis during early myocardial ischemia: Results using three dimensional mapping. Circ Res 1987;61:352-371.
3. Spach MS, Boineau JP: Microfibrosis produces electrical load variations due to loss of side-to-side connections: A major mechanism of structural heart disease arrhythmias. PACE 1997;20:397-413.
4. Goodwin JF: Congestive and hypertrophic cardiomyopathies: A decade of study. Lancet 1970;1:731-739.
5. Ben David J, Zipes DP, Ayers GM, et al: Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early after depolarization after administration of Bay K 8644. J Am Coll Cardiol 1992;20:1576-1584.
6. Belichard P, Pruneau D, Brown NL, et al: Hypertensive myocardial hypertrophy and rhythm disorders: Two possible origins. Arch Mal Coeur 1989;82:1303-1308.
7. Statters DJ, Malik M, Ward DE, et al: QT dispersion: Problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994;5:672-685.
8. Skanes AC, Green MS: What have clinical trials taught us about proarrhythmia? Can J Cardiol 1996;12(Suppl B):20B-26B.
9. Drouin E, Charpentier F, Gauthier C, et al: Evidence for the presence of M cells in the human ventricle. PACE 1993;5:824-837.
10. Antzelevitch C, Sicouri S: Clinical relevance of cardiac arrhythmias generated by after depolarizations. J Am Coll Cardiol 1994;23:259-277.
11. Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Special report: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
12. Cardiac Arrhythmia Suppression Trial II (CAST II) Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
13. IMPACT Research Group: International Mexiletine and Placebo Antiarrhythmic Coronary Trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984;4:1148-1163.
14. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results of randomized controlled trials. JAMA 1993;270:1589-1595.
15. Morganroth J, Boin JE: Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A meta-analysis. Circulation 1991;84:1977-1983.
16. Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
17. Reiffel JA, Estes NAM III, Waldo AL, et al: A consensus report on antiarrhythmic drug use. Clin Cardiol 1994;17:103-116.
18. Beta-Blocker Heart Attack Study Group: The β-blocker heart attack trial. JAMA 1981;246:2073-2074.
19. Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304:801-807.
20. Pedersen TR: The Norwegian Multicenter Study of Timolol after Myocardial Infarction. Circulation 1983; 67:I49-I53.
21. MIAMI Trial Research Group: Metoprolol in Acute Myocardial Infarction (MIAMI): A randomized placebo-controlled international trial (with discussion). Eur Heart J 1985;6:199-226.
22. ISIS-1 (First International Study of Infarct Survival) Collaborative Group: Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. Lancet 1988;1:921-923.
23. Packer M, Bristow MR, Cohn JN, et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
24. Waldo AL, Camm AJ, deRuyter H, et al: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
25. Pratt CM, Camm AJ, Cooper W, et al: Mortality in the Survival With Oral D-Sotalol Trial: Why did patients die? Am J Cardiol 1998;81:869-876.
26. Mason JW, for the Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
27. ESVEM Investigators: Determinants of predicted efficacy of antiarrhythmic drugs in the Electrophysiologic Studies Versus Electrocardiographic Monitoring trial. Circulation 1993;87:323-329.
28. Julian DG, Camm AJ, Frangin G, et al: Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674.
29. Cairns JA, Connolly SJ, Roberts R, et al: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997;349:675-682.
30. Massie BM, Fisher SG, Deedwania PC, et al, for CHF-Stat Investigators: Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996;93:2128-2134
31. Amiodarone Trials Meta-Analysis Investigators: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-1424.
32. DIAMOND Study Group: Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 1997;20:704-710.
33. Singh SN, Berk MR, Yellen LG, et al: Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: A multicenter study. Circulation 1997;96(Suppl I):I-383.
34. Kaber L: Dofetilide, a new class III antiarrhythmic drug reduces hospital admissions for congestive heart failure: Secondary endpoints of the DIAMOND CHF study. (Abstract) J Am Coll Cardiol 1998;31(Suppl A):1015-1039.
35. Pratt CM, Greenway PS, Schoenfeld MH, et al: An exploration of the precision of classifying sudden cardiac death: Implications for the interpretation of clinical trials. Circulation 1996;93:519-524.